Bayer AG – Company Information

Bayer is involved in the development and manufacturing of pharmaceuticals, general health products, veterinary drugs, pesticides, plant biotechnology, polymers, coatings, and adhesives.

Friedrich Bayer and Johann Friedrich Weskott founded Bayer in 1863 in Barmen, Germany.

The first major product that the company developed was Aspirin, also known as acetylsalicylic acid. 

Other well known discoveries include: Heroin (which is now illegal), Prontosil, Ciprofloxacin, and Levitra.

In December 2003, Bayer was made into a holding company, which means that the company’s separate business operations were stripped into individual limited companies (still under the control of Bayer AG). These include: Bayer CropScience AG, Bayer HealthCare AG, Bayer MaterialScience AG, and Bayer Chemicals AG.


Bayer AG logo

  • CEO: Dr. Marijn Dekkers
  • Chairman: Werner Wenning
  • Type: Aktiengesellschaft b
  • Industry: Pharmaceuticals
  • Listed on the Frankfurt Stock Exchange
  • FWB stock symbol: BAYN
  • Revenue: €42.239 billion EUR (2014)
  • Net income: €3,426 million EUR (2014)
  • Earnings per share: €4.14 EUR (2014)
  • Founded: August 1, 1863
  • Headquarters: Leverkusen, Germany
  • Employees: 118,888 (2014)
  • Company subsidiaries: Bayer CropScience, Bayer MaterialScience,Bayer HealthCare Pharmaceuticals, Bayer Schering Pharma

Bayer AG Financial Results, Years Ended December 31

Operating data (in $ millions)20142013
Net sales€42,239€40,157
Cost of goods sold€(20,266)€(19,516)
Gross profit€21,973€20,641
Financial result€(727)€(981)
Income before income taxes€4,207€4,525
Income taxes€(1,021)€(1,082)
Income after income taxes€3,186€3,443
Net income€3,189€3,426
Balance sheet data (in $ millions)
Total assets€70,234€51,317
Noncurrent liabilities€34,513€16,490
Current liabilities€15,503€14,023
Total equity€20,218€20,804
Common share data (in $)
Basic earnings per share€4.14€3.86
Diluted earnings per share€4.14€3.86
Cash flow data (in $ millions)
Net cash provided by (used in) operating activities€5,810€5,171
Net cash provided by (used in) investing activities€(15,539)€(2,581)
Net cash provided by (used in) financing activities€9,736€(2,535)
Cash and cash equivalents at beginning of year€1,662€1,698
Cash and cash equivalents at end of year€1,853€1,662

Source: “Bayer AG Annual Report 2014”